United States · Investor

National Institute of Allergy and Infectious Diseases

Last cheque observed Sep 2026; 43 cheques on record.

Deploying nowInvestment firm

GrantVentureSeries BBiotechnologyHealth Care

Deploying now
50%of best year5cheques in 12 months, 43 on record
Since the last cheque55days00hrs00min00sec
Median round$2.7MRounds led0 of 43Sole investor18 roundsMostly inUnited States, 97%
Pitch National Institute of Allergy and Infectious Diseases

National Institute of Allergy and Infectious Diseases highlights

  1. 01

    5 cheques in the last 12 months

  2. 02

    Mostly Grant and Venture: 88% of its rounds

  3. 03

    Sole investor in 18 rounds, median $2.9M

What they do

Type
Investment firm (from a list, unverified)
Cheque size
Not stated
Sectors
BiotechnologyHealth Care
Based in
Rockville, United States
Cold pitches
Not stated

The record

Every round we can evidence, newest first43 appearances

  1. 2026

    3 rounds

  2. Sept
    HDT BioGrant · US$5.2MWith 1 other
  3. Apr
    ReAlta Life SciencesVenture · US$40MSole investor
  4. Feb
    ILiAD BiotechnologiesSeries D · US$115MWith 3 others
  5. 2025

    9 rounds

  6. Dec
    TretheraGrant · US$2.7MWith 2 others
  7. Nov
    Daré BioscienceGrant · US$3.6MSole investor
  8. Sept
    LactigaVenture · USUndisclosedWith 3 others
  9. Sept
    Sunflower TherapeuticsGrant · US$300KSole investor
  10. Sept
    ScanogenGrant · US$2.9MSole investor
  11. Jun
    MiNK TherapeuticsVenture · USUndisclosedSole investor
  12. May
    Versatope TherapeuticsGrant · US$200KWith 2 others
  13. May
    Calder BiosciencesVenture · USUndisclosedWith 2 others
  14. Mar
    OsivaxSeries B · FR$11MWith 2 others
  15. 2024

    9 rounds

  16. Sept
    Resvita BioGrant · US$2.0MWith 2 others
  17. Aug
    Acenxion BiosystemsSeed · US$1.1MSole investor
  18. Aug
    Aldatu BiosciencesGrant · US$3.0MWith 2 others
  19. Aug
    Moonlight TherapeuticsVenture · US$2.4MWith 1 other
  20. Jun
    ClairyonGrant · US$1.0MSole investor
  21. Apr
    TFF PharmaceuticalsUS$4.8MSole investor
  22. Mar
    Siolta TherapeuticsSeries C · US$12MWith 3 others
  23. Mar
    Phase GenomicsGrant · US$1.5MWith 4 others
  24. Feb
    Blacksmith MedicinesGrant · US$3.3MWith 2 others
  25. 2023

    9 rounds

  26. Oct
    HDT BioGrant · US$1.0MWith 1 other
  27. Sept
    OmnioseGrant · US$3.0MWith 2 others
  28. Aug
    Ceramedix HoldingGrant · US$3.0MSole investor
  29. Aug
    Exavir TherapeuticsGrant · US$3.0MWith 2 others
  30. May
    Sapience TherapeuticsGrant · US$2.0MSole investor
  31. May
    Integrated BioTherapeuticsVenture · US$1.0MWith 1 other
  32. May
    Truly TechnologiesGrant · US$273KSole investor
  33. Jan
    Iaso TherapeuticsGrant · US$125KWith 3 others
  34. Jan
    InDevRSeries B · US$9.0MWith 1 other
  35. 2022

    4 rounds

  36. Nov
    Kovina TherapeuticsGrant · US$275KWith 2 others
  37. Aug
    Institute for Bioscience and Biotechnology ResearchGrant · US$6.9MSole investor
  38. Aug
    Melax TechnologiesGrant · US$300KWith 1 other
  39. Jul
    Intact GenomicsGrant · US$2.9MWith 1 other
  40. 2021

    2 rounds

  41. May
    Nirvana Science, Inc.Venture$867KWith 2 others
  42. Jan
    Kephera DiagnosticsGrant$417KSole investor
  43. 2020

    1 round

  44. Aug
    Enrich TherapeuticsGrant$1.7MWith 2 others
  45. 2019

    3 rounds

  46. Dec
    Antibacterial Resistance Leadership Group (ARLG)Grant$103MSole investor
  47. Jun
    Arisan TherapeuticsGrant$1.0MSole investor
  48. Jan
    Forge TherapeuticsGrant$5.7MWith 1 other

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

Who they invest alongside

The investors most often in the same rounds as National Institute of Allergy and Infectious Diseases. A count of rooms they were both in, not a relationship either has claimed.

National Institutes of HealthGovernment12rounds togetherMassChallengeAccelerator2rounds togetherNational Cancer Institute (NCI)Investment firm2rounds together

Recently backed

The latest companies National Institute of Allergy and Infectious Diseases put money into.

HDT Bio$5.2M · Sept 2026ReAlta Life Sciences$40M · Apr 2026ILiAD Biotechnologies$115M · Feb 2026Trethera$2.7M · Dec 2025LactigaSept 2025Sunflower Therapeutics$300K · Sept 2025

Quick answers about National Institute of Allergy and Infectious Diseases

What does National Institute of Allergy and Infectious Diseases invest in?

National Institute of Allergy and Infectious Diseases invests most often at Grant and Venture (88% of the rounds on record), in sectors such as Biotechnology and Health Care.

How active is National Institute of Allergy and Infectious Diseases?

43 investments on record, 5 of them in the last 12 months. The most recent was in Sept 2026.

What has National Institute of Allergy and Infectious Diseases invested in recently?

Its most recent investments on record: HDT Bio (Grant, Sept 2026), ReAlta Life Sciences (Venture, Apr 2026) and ILiAD Biotechnologies (Series D, Feb 2026).

How big are National Institute of Allergy and Infectious Diseases's cheques?

The median round it joins is $2.7M.

Does National Institute of Allergy and Infectious Diseases lead rounds?

Rarely, if at all: none of its 43 investments on record names it as the lead.

Where does National Institute of Allergy and Infectious Diseases invest?

Most of the companies it backs are in the United States (97%).

Is National Institute of Allergy and Infectious Diseases investing now?

Yes: it is actively investing, with 5 investments in the last 12 months.

Who does National Institute of Allergy and Infectious Diseases invest alongside?

Most often National Institutes of Health (12 rounds together), MassChallenge (2 rounds together) and National Cancer Institute (NCI) (2 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it